Literature DB >> 2777416

Localization and imaging of radiolabelled monoclonal antibody against squamous-cell carcinoma of the head and neck in tumor-bearing nude mice.

J J Quak1, A J Balm, J G Brakkee, R J Scheper, H J Haisma, B J Braakhuis, C J Meijer, G B Snow.   

Abstract

Nude mice carrying human squamous-cell carcinoma xenografts were given i.v. injections of radiolabelled monoclonal antibodies (MAbs). MAb E 48, which reacts with squamous-cell carcinomas, was labelled with 131I, while a second control MAb of similar immunoglobulin subclass was labelled with 125I. Both antibodies were injected simultaneously, then the mice were scanned with a gamma camera or their tissues were removed and antibody uptake was calculated as a percentage of the injected dose. Uptake of E 48 reached a peak value of 16%/g on day 3, while uptake of the control antibody was less than 1.8%/g. By 24 hr after injection tumor could be visualized without subtraction techniques. At days 3 and 7, only xenografts were visible on imaging. These findings suggest that E 48 is capable of high specificity in targeting isotopes to squamous-cell carcinomas in an experimental setting.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2777416     DOI: 10.1002/ijc.2910440327

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Modern imaging techniques and ultrasound-guided aspiration cytology for the assessment of neck node metastases: a prospective comparative study.

Authors:  M W van den Brekel; J A Castelijns; H V Stel; R P Golding; C J Meyer; G B Snow
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

Review 2.  Current perspectives in the use of monoclonal antibodies for detection and treatment of head and neck tumors.

Authors:  J Quak; G van Dongen
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

3.  A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively expressed in stratified squamous and transitional epithelia.

Authors:  J J Quak; A J Balm; G A van Dongen; J G Brakkee; R J Scheper; G B Snow; C J Meijer
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

4.  Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984.

Authors:  A H Schrijvers; M Gerretsen; M van Walsum; B J Braakhuis; J J Quak; G B Snow; G A van Dongen
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Use of monoclonal antibody E48 in diagnosing transitional cell carcinoma of urinary bladder.

Authors:  R Torenbeek; C E Blomjous; J J Quak; S Ybema; C J Meijer
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

6.  Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.

Authors:  M Gerretsen; A H Schrijvers; M van Walsum; B J Braakhuis; J J Quak; C J Meijer; G B Snow; G A van Dongen
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

7.  Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.

Authors:  M Gerretsen; J J Quak; J S Suh; M van Walsum; C J Meijer; G B Snow; G A van Dongen
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

8.  Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts.

Authors:  E Kievit; H M Pinedo; H M Schlüper; H J Haisma; E Boven
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

9.  Expression of tumor-associated glycoantigen, sialyl Lewis(a), in human head and neck squamous cell carcinoma and its application to tumor immunotherapy.

Authors:  K Makino; T Ogata; H Miyake; S Habu; T Nishimura
Journal:  Jpn J Cancer Res       Date:  1994-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.